Fxs0683
Phase 1
Fxs0683 is one of 10 therapeutic programs targeting B-cell Lymphoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
9 competitors in B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Jaypirca
Eli LillyPhase 3
LUNSUMIO
RochePhase 1
Yervoy
Bristol-Myers SquibbPhase 1
Cytoxan
BBaxter Healthcare Corporation
Phase 1
NX-5948
NNurix Therapeutics, Inc.
Phase 3
Rituxan
RochePreclinical
Venclexta
AbbViePreclinical
Fludara
SanofiPreclinical
LP-168
GGuangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
Fxs0683
SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
B-cell Lymphoma1 trial
A Multicenter, Open, Single-arm Phase I Dose-escalation and Dose-expansion Clinical Study: Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of FXS0683 Tablets in Patients With Relapsed or Refractory Hematologic Malignancies.
Recruiting·SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 1·NCT07616089·228 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Fxs0683. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]